Human Chronic Lymphoid Leukemia Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Chronic Lymphoid Leukemia Bone Marrow Mononuclear Cells (BMMCs) (Newly Diagnosed/Untreated) are freshly isolated from the bone marrow of newly diagnosed, treatment-naïve chronic lymphocytic leukemia (CLL) patients, providing a valuable system for studying CLL diagnosis biomarkers. These mononuclear cells primarily consist of abnormal clonal B lymphocytes, along with a minor population of T cells, monocytes, and hematopoietic progenitors, enabling detailed analysis of CLL immune cell profiles. The isolated cells are cryopreserved immediately after isolation Morphologically, CLL B cells appear small and mature with a high nuclear-to-cytoplasmic ratio, and they typically grow in suspension. Cytogenetic profiling reveals common CLL-associated chromosomal abnormalities, such as del(13q), del(11q), or trisomy 12. These cells are functionally characterized by impaired apoptosis, increased survival signaling, and immune evasion. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.